

Skin and Soft Tissue Infections Market - 2023-2031

<https://marketpublishers.com/r/S2857B722233EN.html>

Date: November 2025

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: S2857B722233EN

Abstracts

The Skin and Soft Tissue Infections Market was valued at US\$ 11,283.71 million in 2023 and is anticipated to reach US\$ 21,708.55 million by 2031, at a CAGR of 0.088 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Skin and Soft Tissue Infections Market.

This report delivers a comprehensive overview of the Skin and Soft Tissue Infections Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Skin and Soft Tissue Infections Market. The Skin and Soft Tissue Infections Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Skin and Soft Tissue Infections Market Scope:

By Type

Infected Ulcers

Wound Infections

Abscesses

Cellulitis

Otitis Externa

Others

By Drug Type

Antibiotics

Anti-fungal Agents

Others

By Route of Administration

Topical

Oral

Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

Key Players

GSK Plc

Pfizer Inc.

Merck KGaA

Wellona Pharma

GL Pharma

Basilea Pharmaceutica AG

Invision Medi Sciences Pvt. Ltd.

Intelicure Lifesciences.

Steris Healthcare Pvt Ltd

SNU Biocare

Major Highlights

This report delivers a comprehensive overview of the Skin and Soft Tissue Infections Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Skin and Soft Tissue Infections Market. The Skin and Soft Tissue Infections Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising product development and approvals
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Resistance to the new strains of infectious bacteria
 - 4.1.2.2. XX
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion

6. BY TYPE

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

6.1.2. Market Attractiveness Index, By Type

6.2. Infected Ulcers*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Wound Infections

6.4. Abscesses

6.5. Cellulitis

6.6. Otitis Externa

6.7. Others

7. BY DRUG TYPE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

7.1.2. Market Attractiveness Index, By Drug Type

7.2. Antibiotics*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Anti-fungal Agents

7.4. Others

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Topical*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Oral

8.4. Parenteral

9. BY DISTRIBUTION CHANNEL

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital Pharmacies*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Retail Pharmacies

9.4. Others

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.7.1. U.S.

10.2.7.2. Canada

10.2.7.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.7.1. Germany

10.3.7.2. UK

10.3.7.3. France

10.3.7.4. Italy

10.3.7.5. Spain

10.3.7.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.7.1. Brazil

10.4.7.2. Argentina

10.4.7.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.7.1. China

10.5.7.2. India

10.5.7.3. Japan

10.5.7.4. South Korea

10.5.7.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE

- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

- 12.1. GSK Plc*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio and Description
 - 12.1.3. Financial Overview
 - 12.1.4. Key Developments
- 12.2. Pfizer Inc.
- 12.3. Merck KGaA
- 12.4. Wellona Pharma
- 12.5. GL Pharma
- 12.6. Basilea Pharmaceutica AG
- 12.7. Invision Medi Sciences Pvt. Ltd.
- 12.8. Intelicure Lifesciences.
- 12.9. Steris Healthcare Pvt Ltd
- 12.10. SNU Biocare (*LIST NOT EXHAUSTIVE)

13. APPENDIX

- 13.1. About Us and Services
- 13.2. Contact Us

I would like to order

Product name: Skin and Soft Tissue Infections Market - 2023-2031

Product link: <https://marketpublishers.com/r/S2857B722233EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S2857B722233EN.html>